Breaking News, Trials & Filings

Emergent Gets Positive Results in CLL Trial

Bio-treatment combined with Treanda shows response

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Emergent BioSolutions has posted positive interim results from a Phase II study of the combination of otlertuzumab (TRU-016) and bendamustine versus bendamustine alone in people with relapsed chronic lymphocytic leukemia (CLL). Overall response rate was the primary endpoint of the study.   The combination of treatments produced a higher response rate than bendamustine alone by International Workshop on CLL (IWCLL) and National Cancer Institute (NCI) response criteria. Overall incidence of ad...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters